Nebkliq (Amlodipine Besilate, Nebivolol Hydrochloride)

Nebkliq is used to manage high blood pressure by targeting vascular tone and cardiac output.

• Essential hypertension: reduces systolic and diastolic pressure in patients with primary hypertension.
• Isolated systolic hypertension: helps control elevated systolic readings, especially in older adults.
• Hypertension requiring combination therapy: provides dual action when monotherapy is insufficient.

• Nebkliq combines amlodipine, which blocks L‑type calcium channels in vascular smooth muscle causing vasodilation, with nebivolol, a highly selective β1‑adrenergic antagonist that lowers heart rate and myocardial contractility while enhancing nitric‑oxide release. Together they decrease peripheral resistance and cardiac output, resulting in a sustained reduction of arterial blood pressure.

Common side effects are generally mild and related to the vasodilatory and beta‑blocking actions.

Common Side Effects

• Headache: mild to moderate headache, often transient.
• Peripheral edema: swelling of ankles or feet due to fluid accumulation.
• Flushing: sensation of warmth and redness, especially after the first dose.
• Dizziness: light‑headedness, particularly when standing quickly.
• Fatigue: general tiredness or reduced energy levels.
• Bradycardia: slower than normal heart rate.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Angioedema: swelling of face, lips, tongue, or throat requiring urgent care.
• Hepatic dysfunction: abnormal liver enzymes or jaundice.
• Bronchospasm: tightening of airway muscles, especially in patients with asthma.
• Myocardial infarction: rare occurrence of heart attack.
• Heart block: abnormal heart rhythm that may need medical intervention.

Before initiating Nebkliq, clinicians should evaluate patient history and monitor for potential risks.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Cardiac function assessment: evaluate heart rate and rhythm, especially in patients with conduction disorders.
• Concomitant medication review: consider interactions with other antihypertensives or CYP2D6 substrates.
• Hepatic impairment caution: dose adjustment may be needed in moderate to severe liver disease.
• Discontinuation guidance: avoid abrupt cessation to prevent rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebkliq may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels.
• Other potent antihypertensives (e.g., clonidine, hydralazine): risk of additive blood pressure lowering.
• Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): can enhance bradycardia.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate hypotensive effect, monitor electrolytes.
• NSAIDs: can reduce antihypertensive efficacy, watch renal function.
• Antidiabetic agents: blood glucose may be affected, adjust monitoring.
• Lipid‑lowering drugs (e.g., statins): monitor for increased statin concentrations.
• Alcohol: may enhance dizziness and hypotension.